CN105189556A - 用于实现治疗有效剂量的抗cd47剂的方法 - Google Patents

用于实现治疗有效剂量的抗cd47剂的方法 Download PDF

Info

Publication number
CN105189556A
CN105189556A CN201480015159.9A CN201480015159A CN105189556A CN 105189556 A CN105189556 A CN 105189556A CN 201480015159 A CN201480015159 A CN 201480015159A CN 105189556 A CN105189556 A CN 105189556A
Authority
CN
China
Prior art keywords
agent
dose
hu5f9
days
study
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480015159.9A
Other languages
English (en)
Chinese (zh)
Inventor
斯蒂芬·威林汉
莫林·霍华德
杰·刘
莱文德拉·吗杰提
苏珊·斯威尼·普劳哈斯卡
安妮·K·沃奥科迈
詹斯·彼得·沃奥科迈
欧文·L·唔斯曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51580621&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN105189556(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Priority to CN202210327266.1A priority Critical patent/CN114917336A/zh
Priority to CN202010960541.4A priority patent/CN112245586A/zh
Publication of CN105189556A publication Critical patent/CN105189556A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201480015159.9A 2013-03-15 2014-02-26 用于实现治疗有效剂量的抗cd47剂的方法 Pending CN105189556A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202210327266.1A CN114917336A (zh) 2013-03-15 2014-02-26 用于实现治疗有效剂量的抗cd47剂的方法
CN202010960541.4A CN112245586A (zh) 2013-03-15 2014-02-26 用于实现治疗有效剂量的抗cd47剂的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361800102P 2013-03-15 2013-03-15
US61/800,102 2013-03-15
PCT/US2014/018743 WO2014149477A1 (en) 2013-03-15 2014-02-26 Methods for achieving therapeutically effective doses of anti-cd47 agents

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202210327266.1A Division CN114917336A (zh) 2013-03-15 2014-02-26 用于实现治疗有效剂量的抗cd47剂的方法
CN202010960541.4A Division CN112245586A (zh) 2013-03-15 2014-02-26 用于实现治疗有效剂量的抗cd47剂的方法

Publications (1)

Publication Number Publication Date
CN105189556A true CN105189556A (zh) 2015-12-23

Family

ID=51580621

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201480015159.9A Pending CN105189556A (zh) 2013-03-15 2014-02-26 用于实现治疗有效剂量的抗cd47剂的方法
CN202010960541.4A Pending CN112245586A (zh) 2013-03-15 2014-02-26 用于实现治疗有效剂量的抗cd47剂的方法
CN202210327266.1A Pending CN114917336A (zh) 2013-03-15 2014-02-26 用于实现治疗有效剂量的抗cd47剂的方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202010960541.4A Pending CN112245586A (zh) 2013-03-15 2014-02-26 用于实现治疗有效剂量的抗cd47剂的方法
CN202210327266.1A Pending CN114917336A (zh) 2013-03-15 2014-02-26 用于实现治疗有效剂量的抗cd47剂的方法

Country Status (11)

Country Link
US (8) US9623079B2 (https=)
EP (3) EP3792285A1 (https=)
JP (5) JP6426693B2 (https=)
CN (3) CN105189556A (https=)
AU (4) AU2014238105B2 (https=)
CA (1) CA2903773A1 (https=)
DK (1) DK2970493T3 (https=)
ES (1) ES2728066T3 (https=)
IL (1) IL241347B (https=)
PT (1) PT2970493T (https=)
WO (1) WO2014149477A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109071676A (zh) * 2016-01-21 2018-12-21 小利兰·斯坦福大学托管委员会 使用免疫调节剂的组合的癌症治疗
CN115350276A (zh) * 2016-04-15 2022-11-18 小利兰·斯坦福大学托管委员会 用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009205665B2 (en) 2008-01-15 2013-12-05 The Board Of Trustees Of The Leland Stanford Junior University Methods for manipulating phagocytosis mediated by CD47
CA2965198C (en) * 2008-01-15 2021-02-16 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
US11072655B2 (en) * 2008-01-15 2021-07-27 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
US9221908B2 (en) 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
MX2015007446A (es) 2012-12-12 2015-12-07 Vasculox Inc Anticuerpos terapeuticos para cd47.
PT2970493T (pt) * 2013-03-15 2019-06-27 Univ Leland Stanford Junior Métodos para obter doses terapeuticamente eficazes de agentes anti-cd47
ES2765483T3 (es) 2013-09-18 2020-06-09 Univ Leland Stanford Junior Modulación de las vías de eferocitosis para el tratamiento de una enfermedad aterosclerótica
US10550187B2 (en) * 2014-10-24 2020-02-04 Incept, Llc Extra luminal scaffold
RU2576614C1 (ru) * 2015-01-19 2016-03-10 ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ "33 ЦЕНТРАЛЬНЫЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИСПЫТАТЕЛЬНЫЙ ИНСТИТУТ" Минобороны России Способ поиска точки с дробным эффектом при определении эффективных доз веществ методом "одной точки"
EP3247464B1 (en) 2015-01-21 2019-09-18 The Board of Trustees of the Leland Stanford Junior University Use of tlr agonist and anti-cd47 agent to enhance phagocytosis of cancer cells
US11253588B2 (en) 2015-02-27 2022-02-22 The Board Of Trustees Of The Leland Stanford Junior University Combination therapy for treatment of coronary artery disease
WO2017027422A1 (en) 2015-08-07 2017-02-16 Alexo Therapeutics Inc. Constructs having a sirp-alpha domain or variant thereof
WO2017040932A1 (en) 2015-09-04 2017-03-09 Primatope Therapeutics Inc. Humanized anti-cd40 antibodies and uses thereof
BR112018005322A2 (pt) 2015-09-18 2018-12-11 Arch Oncology, Inc. anticorpo monoclonal ou seu fragmento de ligação a antígenos, composição farmacêutica, anticorpo monoclonal ou seu fragmento de ligação a antígenos para uso, método de tratamento de lesão de isquemia-reperfusão, método de tratamento de câncer em um paciente humano, método de avaliação da expressão de cd47 em células tumorais e/ou imunes usando um anticorpo monoclonal ou seu fragmento de ligação a antígenos
NZ741324A (en) 2015-09-21 2021-09-24 Erasmus Univ Medical Center Anti-cd47 antibodies and methods of use
AU2016365829B2 (en) * 2015-12-11 2020-02-06 The Board Of Trustees Of The Leland Stanford Junior University Treatment of cancer with dual targeting of CD47 and EGFR
US9957576B2 (en) 2016-04-21 2018-05-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for determining responsiveness to an anti-CD47 agent
WO2017190148A1 (en) 2016-04-29 2017-11-02 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for the prevention and treatment of surgical adhesions
JP7241677B2 (ja) 2016-07-19 2023-03-17 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｃｄ４７併用療法
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
EP3529276A4 (en) 2016-10-21 2020-06-17 Arch Oncology, Inc. CD47 THERAPEUTIC ANTIBODIES
EP3532497B1 (en) * 2016-10-26 2024-07-24 The Board of Trustees of the Leland Stanford Junior University Modified immunoglobulin hinge regions to reduce hemagglutination
WO2018081898A1 (en) 2016-11-03 2018-05-11 Trillium Therapeutics Inc. Improvements in cd47 blockade therapy by hdac inhibitors
EP3589368A4 (en) 2017-02-28 2021-03-24 The Board of Trustees of the Leland Stanford Junior University ANTIFIBROTIC ACTIVITY OF CD47 BLOCKING
US11078272B2 (en) 2017-03-09 2021-08-03 The Board Of Trustees Of The Leland Stanford Junior University Treatment of pediatric brain tumors with targeting of CD47 pathway
SI3642242T1 (sl) * 2017-06-21 2024-05-31 The Board of Trustees of the Leland Stanford Junior University Office of the General Counsel Parametri odmerjanja za terapije, ki ciljajo na CD47, za hematološke malignosti
JP7262440B2 (ja) 2017-08-02 2023-04-21 フェインズ セラピューティクス，インコーポレーテッド 抗ｃｄ４７抗体及びその使用
PL3697819T3 (pl) 2017-10-18 2023-03-06 Forty Seven, Inc. Leczenie nowotworu złośliwego jajnika anty-cd47 i anty-pd-l1
SI4177270T1 (sl) 2017-10-18 2024-10-30 Forty Seven, Inc. Terapija za raka jajčnikov na osnovi sredstva proti cd47
KR20200091901A (ko) 2017-12-01 2020-07-31 시애틀 지네틱스, 인크. 암을 치료하기 위한 cd47 항체 및 이의 용도
AU2019218271B2 (en) * 2018-02-12 2024-12-12 Forty Seven, LLC Anti-cancer regimen using anti-CD47 and anti-CD20 antibodies
MX2020009774A (es) 2018-03-21 2020-10-08 Alx Oncology Inc Anticuerpos contra proteína alfa reguladora de señal y métodos de uso.
SG11202102851XA (en) 2018-09-27 2021-04-29 Celgene Corp SIRPa BINDING PROTEINS AND METHODS OF USE THEREOF
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
WO2020163692A1 (en) * 2019-02-08 2020-08-13 The Board Of Trustees Of The Leland Stanford Junior University Treatment of cutaneous t cell lymphoma with targeting of cd47 pathway
EP3976658A4 (en) * 2019-05-24 2023-06-07 Forty Seven, Inc. Regimes for co-administration of immunotherapeutic agents against c-kit and cd47
BR112021024003A2 (pt) 2019-05-31 2022-04-19 Alx Oncology Inc Métodos de tratamento de câncer com fusão sirp alfa-fc em combinação com um inibidor de checkpoint imunológico
CN114206912B (zh) * 2019-06-07 2025-02-11 Alx肿瘤生物技术公司 用于在血清学测定中减少结合cd47的药物的干扰的方法和试剂
CN114555123B (zh) 2019-10-18 2024-04-02 四十七公司 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法
AU2020394204A1 (en) 2019-11-27 2022-06-02 ALX Oncology Inc. Combination therapies for treating cancer
JP7369297B2 (ja) 2019-12-17 2023-10-25 ファイザー・インク Ｃｄ４７、ｐｄ－ｌ１に特異的な抗体、およびその使用
CA3194577A1 (en) * 2020-10-09 2022-04-14 Sonja SCHREPFER Methods for triggering safety killing mechanisms using a cd47-sirp.alpha. blockade agent
WO2022130016A1 (en) 2020-12-18 2022-06-23 Instil Bio (Uk) Limited Tumor infiltrating lymphocytes and anti-cd47 therapeutics
JP2024520902A (ja) 2021-05-13 2024-05-27 エーエルエックス オンコロジー インコーポレイテッド がんを治療するための併用療法
CA3227223A1 (en) * 2021-07-28 2023-02-02 Actinium Pharmaceuticals, Inc. Combination radioimmunotherapy and cd47 blockade in the treatment of cancer
US12234294B2 (en) 2021-11-05 2025-02-25 Kiniksa Pharmaceuticals, Gmbh Pharmaceutical composition of a humanized anti-CD40 antibody
KR102876945B1 (ko) * 2021-11-19 2025-10-29 한국과학기술연구원 표적 세포로의 활성 제약 성분의 적혈구-매개 전달을 위한 치료 화합물
AU2023205152A1 (en) * 2022-01-10 2024-07-18 Kiniksa Pharmaceuticals, Gmbh Methods of treating or reducing risk of transplant rejection
WO2023154578A1 (en) 2022-02-14 2023-08-17 Sana Biotechnology, Inc. Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
WO2023183313A1 (en) 2022-03-22 2023-09-28 Sana Biotechnology, Inc. Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
EP4619435A1 (en) 2022-11-16 2025-09-24 Boehringer Ingelheim International GmbH Predictive efficacy biomarkers for anti-sirpa antibodies
WO2024124107A2 (en) 2022-12-09 2024-06-13 Pfizer Inc. Cd47 blocking agent and anti-cd20 / anti-cd3 bispecific antibody combination therapy
CN120390653A (zh) 2022-12-09 2025-07-29 辉瑞大药厂 Cd47阻断剂及抗bcma/抗cd3双特异性抗体的组合疗法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120282174A1 (en) * 2009-09-15 2012-11-08 Weissman Irving L Synergistic Anti-CD47 Therapy for Hematologic Cancers

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020052309A1 (en) * 1996-09-11 2002-05-02 Athanasius A. Anagnostou Method of treating endothelial injury
AU2002315052A1 (en) * 2001-05-15 2002-11-25 Emory University Polynucleotides and polypeptides relating to the modulation of sirp alpha-cd47
US20040213792A1 (en) 2003-04-24 2004-10-28 Clemmons David R. Method for inhibiting cellular activation by insulin-like growth factor-1
US20070113297A1 (en) * 2005-09-13 2007-05-17 Yongguang Yang Methods and compositions for inhibition of immune responses
US8377448B2 (en) 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
US20100239578A1 (en) 2007-10-11 2010-09-23 University Health Network Modulation of sirp-alpha - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor
CN101456911A (zh) * 2007-12-12 2009-06-17 江苏豪森药业股份有限公司 促红细胞生成素模拟肽衍生物及其可药用盐和其制备方法与用途
CA2965198C (en) 2008-01-15 2021-02-16 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
AU2009205665B2 (en) 2008-01-15 2013-12-05 The Board Of Trustees Of The Leland Stanford Junior University Methods for manipulating phagocytosis mediated by CD47
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
WO2011041453A1 (en) * 2009-09-29 2011-04-07 The Board Of Trustees Of The Leland Stanford Junior University Isolation and use of melanoma cancer stem cells
HRP20221260T1 (hr) 2010-05-14 2023-03-03 The Board Of Trustees Of The Leland Stanford Junior University Humanizirana i kimerna monoklonska protutijela za cd47
SI2804617T1 (sl) * 2012-01-17 2020-10-30 The Board Of Trustees Of The Leland Stanford Junior University Visokoafinitetni SIRP-alfa reagenti
US20140140989A1 (en) * 2012-02-06 2014-05-22 Inhibrx Llc Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof
KR102338833B1 (ko) * 2012-02-06 2021-12-13 인히브릭스, 인크. Cd47 항체 및 그 사용 방법
BR112015000167B1 (pt) 2012-07-06 2021-11-23 Genmab B.V. Proteína dimérica, proteína, composição, kit de partes e seus usos, bem como método para aumentar a oligomerização em solução de uma proteína dimérica compreendendo um primeiro e segundo polipeptídeo, cada um compreendendo pelo menos as regiões ch2 e ch3 de uma cadeia pesada de igg1 humana e proteína dimérica variante
CN105101997B (zh) * 2013-02-06 2018-11-09 印希彼有限合伙公司 不减少血小板和不减少血红细胞的cd47抗体及其使用方法
PT2970493T (pt) * 2013-03-15 2019-06-27 Univ Leland Stanford Junior Métodos para obter doses terapeuticamente eficazes de agentes anti-cd47

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120282174A1 (en) * 2009-09-15 2012-11-08 Weissman Irving L Synergistic Anti-CD47 Therapy for Hematologic Cancers

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
（英）莫菲特等著，张耀洲译: "《滋养层生物学与病理学》", 31 May 2008 *
STEPHEN B.WILLINGHAM等: "The CD47-signal regulatory protein alpha(SIRPα) interaction is a therapeutic target for human solid tumors", 《PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES》 *
中国科学技术协会: "《生物学学科发展报告 2007-2008》", 28 February 2008 *
陈衍等: "癌性贫血的最新临床研究进展", 《现代肿瘤医学》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109071676A (zh) * 2016-01-21 2018-12-21 小利兰·斯坦福大学托管委员会 使用免疫调节剂的组合的癌症治疗
CN115350276A (zh) * 2016-04-15 2022-11-18 小利兰·斯坦福大学托管委员会 用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法

Also Published As

Publication number Publication date
JP2019031545A (ja) 2019-02-28
JP2016513640A (ja) 2016-05-16
EP2970493A1 (en) 2016-01-20
EP3792285A1 (en) 2021-03-17
JP2022050544A (ja) 2022-03-30
JP2023075275A (ja) 2023-05-30
PT2970493T (pt) 2019-06-27
US20170145096A1 (en) 2017-05-25
AU2019200294A1 (en) 2019-02-07
US20210079093A1 (en) 2021-03-18
EP3536709A1 (en) 2019-09-11
AU2020270485A1 (en) 2020-12-17
EP2970493B1 (en) 2019-04-03
JP2020128414A (ja) 2020-08-27
US20220251199A1 (en) 2022-08-11
JP7562736B2 (ja) 2024-10-07
DK2970493T3 (da) 2019-05-13
EP2970493A4 (en) 2016-11-02
US12258399B2 (en) 2025-03-25
JP7007422B2 (ja) 2022-01-24
AU2020270485B2 (en) 2024-05-23
AU2019200294B2 (en) 2020-08-20
AU2014238105A1 (en) 2015-08-27
JP6704974B2 (ja) 2020-06-03
US11603404B2 (en) 2023-03-14
US20220289845A1 (en) 2022-09-15
US11136391B2 (en) 2021-10-05
CA2903773A1 (en) 2014-09-25
ES2728066T3 (es) 2019-10-22
US20230303688A1 (en) 2023-09-28
US10301387B2 (en) 2019-05-28
JP7246528B2 (ja) 2023-03-27
US20210380689A1 (en) 2021-12-09
HK1219956A1 (en) 2017-04-21
IL241347B (en) 2020-03-31
JP6426693B2 (ja) 2018-11-21
WO2014149477A1 (en) 2014-09-25
AU2014238105B2 (en) 2018-11-15
US11104731B2 (en) 2021-08-31
WO2014149477A8 (en) 2014-11-06
IL241347A0 (en) 2015-11-30
US12258403B2 (en) 2025-03-25
US9623079B2 (en) 2017-04-18
US20160008429A1 (en) 2016-01-14
US20190218289A1 (en) 2019-07-18
CN114917336A (zh) 2022-08-19
AU2024210996A1 (en) 2024-09-05
US11518806B2 (en) 2022-12-06
CN112245586A (zh) 2021-01-22

Similar Documents

Publication Publication Date Title
US11603404B2 (en) Methods for treating cancer by achieving therapeutically effective doses of anti-CD47 antibody
EP3311824A1 (en) Cd47 targeted therapies for the treatment of infectious disease
KR20180134367A (ko) 암의 치료에서 항-cd47 제제의 치료적으로 효과적인 용량을 결정하고 달성하는 방법
HK40035245A (en) Methods for achieving therapeutically effective doses of anti-cd47 agents
HK40074499A (en) Methods for achieving therapeutically effective doses of anti-cd47 agents
HK40042379A (en) Methods for achieving therapeutically effective doses of anti-cd47 agents
HK40108467A (zh) 用於确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法
HK1219956B (en) Methods for achieving therapeutically effective doses of anti-cd47 agents

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20151223

RJ01 Rejection of invention patent application after publication